Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV.

ABSTRACT:

Objectives

People with HIV (PWH) experience a greater risk of morbidity and mortality following COVID-19 infection, and poorer immunological responses to several vaccines. We explored existing evidence regarding the immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccines in PWH compared with controls.

Methods

We conducted a systematic search of electronic databases from January 2020 until June 2022, in addition to conference databases, to identify studies comparing clinical, immunogenicity, and safety in PWH and controls. We compared results between those with low (<350 cells/μl) and high (>350 cells/μl) CD4 + T-cell counts where possible. We performed a meta-analysis of seroconversion and neutralization responses to calculate a pooled risk ratio as the measure of e

SUBMITTER: Griffin DWJ 

PROVIDER: S-EPMC10328433 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature